Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Published:2019-07 Issue:7 Volume:17 Page:855-883
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Ajani Jaffer A.¹,D’Amico Thomas A.²,Bentrem David J.³,Chao Joseph⁴,Corvera Carlos⁵,Das Prajnan¹,Denlinger Crystal S.⁶,Enzinger Peter C.⁷,Fanta Paul⁸,Farjah Farhood⁹,Gerdes Hans¹⁰,Gibson Michael¹¹,Glasgow Robert E.¹²,Hayman James A.¹³,Hochwald Steven¹⁴,Hofstetter Wayne L.¹,Ilson David H.¹⁰,Jaroszewski Dawn¹⁵,Johung Kimberly L.¹⁶,Keswani Rajesh N.³,Kleinberg Lawrence R.¹⁷,Leong Stephen¹⁸,Ly Quan P.¹⁹,Matkowskyj Kristina A.²⁰,McNamara Michael²¹,Mulcahy Mary F.³,Paluri Ravi K.²²,Park Haeseong²³,Perry Kyle A.²⁴,Pimiento Jose²⁵,Poultsides George A.²⁶,Roses Robert²⁷,Strong Vivian E.¹⁰,Wiesner Georgia¹¹,Willett Christopher G.²,Wright Cameron D.²⁸,McMillian Nicole R.²⁹,Pluchino Lenora A.²⁹

Affiliation:

1. 1The University of Texas MD Anderson Cancer Center;

2. 2Duke Cancer Institute;

3. 3Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

4. 4City of Hope National Medical Center;

5. 5UCSF Helen Diller Family Comprehensive Cancer Center;

6. 6Fox Chase Cancer Center;

7. 7Dana-Farber/Brigham and Women’s Cancer Center;

8. 8UC San Diego Moores Cancer Center;

9. 9Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

10. 10Memorial Sloan Kettering Cancer Center;

11. 11Vanderbilt-Ingram Cancer Center;

12. 12Huntsman Cancer Institute at the University of Utah;

13. 13University of Michigan Rogel Cancer Center;

14. 14Roswell Park Comprehensive Cancer Center;

15. 15Mayo Clinic Cancer Center;

16. 16Yale Cancer Center/Smilow Cancer Hospital;

17. 17The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

18. 18University of Colorado Cancer Center;

19. 19Fred & Pamela Buffett Cancer Center;

20. 20University of Wisconsin Carbone Cancer Center;

21. 21Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

22. 22O'Neal Comprehensive Cancer Center at UAB;

23. 23Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

24. 24The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

25. 25Moffitt Cancer Center;

26. 26Stanford Cancer Institute;

27. 27Abramson Cancer Center at the University of Pennsylvania;

28. 28Massachusetts General Hospital Cancer Center; and

29. 29National Comprehensive Cancer Network

Abstract

AbstractEsophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 728 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of length of oral resection margin and survival in esophageal cancer surgery after neoadjuvant therapy: A retrospective propensity score-matched study;Surgery;2024-10

2. Tumor‐Resident Microbiota‐Based Risk Model Predicts Neoadjuvant Therapy Response of Locally Advanced Esophageal Squamous Cell Carcinoma Patients;Advanced Science;2024-09-13

3. Vasculogenic mimicry triggers early recidivation and resistance to adjuvant therapy in esophageal cancer;BMC Cancer;2024-09-11

4. Comparison of Neoadjuvant Chemoradiotherapy versus Chemoradiotherapy Plus Immunotherapy for Esophageal Squamous Cell Carcinoma in a Real-World Multicenter Cohort: A Propensity Score Matching Study;2024-09-09

5. Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma;BMC Gastroenterology;2024-09-02